Home › Breast Cancer › NCT02610439

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples

Who can join

All ages · All sexes

Inclusion Criteria:

* European American patients with DNA available and designated case or control
* African American patients with DNA available and designated case or control status
* Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel

About the study

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.

What is being tested

• Laboratory Biomarker Analysis (other)

Sponsor: National Cancer Institute (NCI) · Participants: 575 · Started: Mar 25, 2014

Contact the study team

Official record on ClinicalTrials.gov — NCT02610439

Locations in the U.S.

Conditions

• Breast Cancer

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.